Tesamorelin: Clinical Trials of Visceral Fat in People With HIV

How to read this program

The core clinical evidence for tesamorelin is not a general-obesity program. It is a program in adults with HIV and abdominal fat accumulation. The endpoint that organizes the pivotal trials is visceral adipose tissue, measured by imaging, not scale weight as the main question.^1,2

There are two independent Phase 3 trials: one with 412 participants, published in 2007, and one with 404, published with a safety extension. A 2010 pooled analysis summarizes those two programs. The pooled paper is not a third trial.^1,2,4

This page is not a treatment guide and does not reproduce administration schedules as use instructions. Approved-product context is in the tesamorelin hub and in EGRIFTA, FDA & WADA.

Phase 2 context

Before the pivotals, tesamorelin was investigated as a GHRH analogue for the same clinical problem: central fat accumulation in people with HIV. The pivotals are the studies that fix the size and endpoint later read alongside the 2010 approval. This page does not treat Phase 2 as the basis of the indication.^7,1

The 412-participant trial (NEJM 2007)

Falutz and colleagues published a randomized controlled trial in The New England Journal of Medicine: “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” Participants were 412 adults with HIV and abdominal fat accumulation. The primary endpoint was change in visceral adipose tissue.¹

That design answers a body-composition question in HIV-associated lipodystrophy. It does not answer whether tesamorelin is a weight-loss drug for general obesity. Visceral-fat reduction in that population does not, by itself, become weight-loss efficacy for every person.¹ Visceral fat is not body weight

Second pivotal Phase 3 (404 participants)

The second pivotal program randomized 404 people with HIV and abdominal fat accumulation. The trial registry identifier is NCT00435136. The published report describes a placebo-controlled efficacy period and a safety extension, with visceral adipose tissue as the primary endpoint.^2,3

In the efficacy phase, investigational tesamorelin showed a visceral-adipose-tissue reduction versus placebo. The report also describes trunk-fat and waist-circumference changes without an equivalent change in limb subcutaneous fat. Those figures belong to the trial and that population. They are not use instructions and are not read here as a scale-weight result.²

2010 pooled analysis

Falutz and colleagues published in JCEM a pooled analysis of the two multicenter, double-blind, placebo-controlled Phase 3 trials, with extension data. The title says what it is: a pooled analysis of two Phase 3 programs, not a third trial that enrolled a new independent population.⁴

Pooling can refine the visceral-adipose-tissue effect by combining the two pivotals. Counting it as a third independent trial would inflate the evidence map. This hub cites it as a synthesis, not as a third pivotal.

Extension and discontinuation

Extension evidence, including the 2008 publication, shows that visceral-fat reductions persisted while investigational treatment continued and that visceral fat reaccumulated after discontinuation.^5,2

That explains that observed clinical effects were treatment-context dependent. It is not translated here into a duration recommendation, or into an instruction about “how long to use” a product, and still less Peptra research material.

FDA approval context

FDA approved tesamorelin in the United States on 10 November 2010 for EGRIFTA products. Current labeling keeps the indication in HIV-infected adults with lipodystrophy and keeps the statement that the product is not indicated for weight-loss management.^7,6

The 2014 and 2019 liver studies, and the 2024 integrase-inhibitor subgroup analysis, do not replace these pivotals and do not create a new indication. They are read on their own pages.^8,9,10

Trial table

What not to do with this evidence

• Do not convert visceral-fat reduction into a percentage of body-weight loss.
• Do not generalize to general obesity or to people without HIV.
• Do not count the pooled analysis as a third pivotal.
• Do not read the extension as a duration recommendation.
• Do not assign these results to Peptra’s research vial as if it were the studied product.